sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism play important roles in AMD. | HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism may play important roles in AMD. | 1 |
In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism contributes to the development of AMD. | In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism does not contribute to the development of AMD. | -1 |
In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism contributes to the development of AMD. | There is no evidence that the rs2230199 polymorphism contributes to the development of AMD. | 0 |
In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism contributes to the development of AMD. | In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism may contribute to the development of AMD. | 1 |
Visual acuity outcomes were similar between aflibercept and ranibizumab groups; at one year, participants in the aflibercept groups showed mean change in best-corrected visual acuity (BCVA) from baseline similar to that of participants in the ranibizumab groups (mean difference (MD) -0.15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, 95% confidence interval (95% CI) -1.47 to 1.17; high-quality evidence). | Visual acuity outcomes were different between aflibercept and ranibizumab groups; at one year, participants in the aflibercept groups showed mean change in best-corrected visual acuity (BCVA) from baseline similar to that of participants in the ranibizumab groups (mean difference (MD) -0.15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, 95% confidence interval (95% CI) -1.47 to 1.17; high-quality evidence). | -1 |
Current available information on adverse effects of each medication suggests that the safety profile of aflibercept is comparable with that of ranibizumab; however, the number of participants who experienced adverse events was small, leading to imprecise estimates of absolute and relative effect sizes. | Current available information on adverse effects of each medication suggests that the safety profile of aflibercept is not comparable with that of ranibizumab; however, the number of participants who experienced adverse events was small, leading to imprecise estimates of absolute and relative effect sizes. | -1 |
Current available information on adverse effects of each medication suggests that the safety profile of aflibercept is comparable with that of ranibizumab; however, the number of participants who experienced adverse events was small, leading to imprecise estimates of absolute and relative effect sizes. | Current available information on adverse effects of each medication suggests that the safety profile of aflibercept is higher than that of ranibizumab; however, the number of participants who experienced adverse events was small, leading to imprecise estimates of absolute and relative effect sizes. | -1 |
The eight-week dosing regimen of aflibercept represents reduced treatment requirements in comparison with monthly dosing regimens and thus has the potential to reduce treatment burden and risks associated with frequent injections. | The eight-week dosing regimen of aflibercept represents reduced treatment requirements in comparison with monthly dosing regimens and thus reduces treatment burden and risks associated with frequent injections. | 1 |
There is no benefit with submacular surgery in most people with subfoveal choroidal neovascularisation due to AMD in terms of prevention of visual loss. | There is some benefit with submacular surgery in most people with subfoveal choroidal neovascularisation due to AMD in terms of prevention of visual loss. | -1 |
Furthermore, the risk of developing cataract and retinal detachment increases after surgery. | Furthermore, the risk of developing cataract and retinal detachment does not increase after surgery. | -1 |
Furthermore, the risk of developing cataract and retinal detachment increases after surgery. | Furthermore, the risk of developing cataract and retinal detachment decreases after surgery. | -1 |
Furthermore, the risk of developing cataract and retinal detachment increases after surgery. | There is no evidence that the risk of developing cataract and retinal detachment increases after surgery. | 0 |
Furthermore, the risk of developing cataract and retinal detachment increases after surgery. | Furthermore, the risk of developing cataract and retinal detachment may increase after surgery. | 1 |
The study demonstrates that despite limited specificity, automated retinal image analysis may potentially be valuable in different DR screening scenarios with a relatively high sensitivity and a substantial workload reduction. | The study demonstrates that despite limited specificity, automated retinal image analysis is valuable in different DR screening scenarios with a relatively high sensitivity and a substantial workload reduction. | 1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation does not reduce the chances of visual loss but increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | -1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation increases the chances of visual loss but increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | -1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | There is no evidence that laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | 0 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation may reduce the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | 1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation reduces the chances of visual loss but does not increase those of partial to complete resolution of DMO compared to no intervention at one to three years. | -1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation reduces the chances of visual loss but reduces those of partial to complete resolution of DMO compared to no intervention at one to three years. | -1 |
Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. | Laser photocoagulation reduces the chances of visual loss and may increase those of partial to complete resolution of DMO compared to no intervention at one to three years. | 1 |
Subthreshold photocoagulation, particularly the micropulse technique, may be as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | Subthreshold photocoagulation, particularly the micropulse technique, may be not as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | -1 |
Subthreshold photocoagulation, particularly the micropulse technique, may be as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | Subthreshold photocoagulation, particularly the micropulse technique, may be more effective than standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | -1 |
Subthreshold photocoagulation, particularly the micropulse technique, may be as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | Subthreshold photocoagulation, particularly the micropulse technique, are as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO. | 1 |
It does seem that topical steroids are better than no anti-inflammatory treatment after glaucoma surgery, but further research is recommended. | It does not seem that topical steroids are better than no anti-inflammatory treatment after glaucoma surgery, but further research is recommended. | -1 |
It does seem that topical steroids are better than no anti-inflammatory treatment after glaucoma surgery, but further research is recommended. | It does seem that topical steroids are worse than no anti-inflammatory treatment after glaucoma surgery, but further research is recommended. | -1 |
Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | Patients with AMD of any lesion type do not benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | -1 |
Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | There is no evidence that patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | 0 |
Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | Patients with AMD of any lesion type may benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. | 1 |
Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. | Patients who continued treatment with either drug did not appear to maintain benefits after 2 years of follow-up. | -1 |
Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. | There is no evidence that patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. | 0 |
Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. | Trabeculectomy with beta irradiation does not have a lower risk of surgical failure compared to trabeculectomy alone. | -1 |
Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. | Trabeculectomy with beta irradiation has a higher risk of surgical failure compared to trabeculectomy alone. | -1 |
Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. | There is no evidence that trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. | 0 |
Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. | Trabeculectomy with beta irradiation may have a lower risk of surgical failure compared to trabeculectomy alone. | 1 |
The overall results support a positive association between CKD and AMD, although some limitations exist. | The overall results do not support a positive association between CKD and AMD, although some limitations exist. | -1 |
The overall results support a positive association between CKD and AMD, although some limitations exist. | The overall results support a negative association between CKD and AMD, although some limitations exist. | -1 |
OSA was a risk factor for glaucoma. | OSA was not a risk factor for glaucoma. | -1 |
OSA was a risk factor for glaucoma. | There is no evidence that OSA was a risk factor for glaucoma. | 0 |
OSA was a risk factor for glaucoma. | OSA might be a risk factor for glaucoma. | 1 |
The presence of pseudodrusen was associated with a 1.5 times higher risk of developing nAMD, a 4.7 times higher risk of developing GA, and a 2 times higher risk of developing late AMD. | The presence of pseudodrusen was associated with a 1.5 times lower risk of developing nAMD, a 4.7 times lower risk of developing GA, and a 2 times lower risk of developing late AMD. | -1 |
The presence of pseudodrusen was associated with a 1.5 times higher risk of developing nAMD, a 4.7 times higher risk of developing GA, and a 2 times higher risk of developing late AMD. | The presence of pseudodrusen might be associated with a 1.5 times higher risk of developing nAMD, a 4.7 times higher risk of developing GA, and a 2 times higher risk of developing late AMD. | 1 |
A meta-analysis of evidence from eleven studies (41,690 study participants) shows that high serum levels (>3 mg/L) of CRP are associated with a two-fold likelihood of late onset AMD, compared to low levels (<1mg/L). | A meta-analysis of evidence from eleven studies (41,690 study participants) shows that high serum levels (>3 mg/L) of CRP are not associated with a two-fold likelihood of late onset AMD, compared to low levels (<1mg/L). | -1 |
A meta-analysis of evidence from eleven studies (41,690 study participants) shows that high serum levels (>3 mg/L) of CRP are associated with a two-fold likelihood of late onset AMD, compared to low levels (<1mg/L). | A meta-analysis of evidence from eleven studies (41,690 study participants) shows that high serum levels (>3 mg/L) of CRP may be associated with a two-fold likelihood of late onset AMD, compared to low levels (<1mg/L). | 1 |
This analysis revealed the synergistic and positive multiplicative effect of these two genes indicating that there is a common pathway of ARMS2/LOC387715 and CFH in AMD pathogenesis which may be the complement system pathway. | This analysis revealed the synergistic and positive multiplicative effect of these two genes indicating that there may be a common pathway of ARMS2/LOC387715 and CFH in AMD pathogenesis which may be the complement system pathway. | 1 |
Our meta-analysis indicates that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. | Our meta-analysis indicates that LIPC rs10468017 variant is not associated with a reduced risk of advanced AMD. | -1 |
Our meta-analysis indicates that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. | Our meta-analysis indicates that LIPC rs10468017 variant is associated with a increased risk of advanced AMD. | -1 |
Our meta-analysis indicates that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. | There is no evidence that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. | 0 |
Our meta-analysis indicates that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. | Our meta-analysis indicates that LIPC rs10468017 variant might be associated with a reduced risk of advanced AMD. | 1 |
Meta-analysis of randomized, controlled trials shows that SLT is non-inferior to ALT and medication in IOP reduction and also in achieving treatment success. | Meta-analysis of randomized, controlled trials shows that SLT is inferior to ALT and medication in IOP reduction and also in achieving treatment success. | -1 |
Meta-analysis of randomized, controlled trials shows that SLT is non-inferior to ALT and medication in IOP reduction and also in achieving treatment success. | Meta-analysis of randomized, controlled trials shows that SLT is non-superior to ALT and medication in IOP reduction and also in achieving treatment success. | -1 |
Meta-analysis of randomized, controlled trials shows that SLT is non-inferior to ALT and medication in IOP reduction and also in achieving treatment success. | Meta-analysis of randomized, controlled trials shows that SLT may be non-inferior to ALT and medication in IOP reduction and also in achieving treatment success. | 1 |
Number of medications reduction is similar between SLT and ALT. | There is no evidence that number of medications reduction is similar between SLT and ALT. | 0 |
The results of this meta-analysis of observational studies demonstrate that insulin use is a risk factor for diabetic macular edema. However, available data are still sparse, and in-depth analyses of the assessed associations in the context of additional longitudinal studies are highly desirable to enable more precise estimates and a better understanding of the role of insulin use in incidence of diabetic macular edema. | The results of this meta-analysis of observational studies demonstrate that insulin use is not a risk factor for diabetic macular edema. However, available data are still sparse, and in-depth analyses of the assessed associations in the context of additional longitudinal studies are highly desirable to enable more precise estimates and a better understanding of the role of insulin use in incidence of diabetic macular edema. | -1 |
The present meta-analysis indicated that the T allelic in rs1883025 variant was significantly associated with the risk of developing AMD, particularly at the early stage. | The present meta-analysis indicated that the T allelic in rs1883025 variant was not significantly associated with the risk of developing AMD, particularly at the early stage. | -1 |
The present meta-analysis indicated that the T allelic in rs1883025 variant was significantly associated with the risk of developing AMD, particularly at the early stage. | There is no evidence that the T allelic in rs1883025 variant was significantly associated with the risk of developing AMD, particularly at the early stage. | 0 |
The present meta-analysis indicated that the T allelic in rs1883025 variant was significantly associated with the risk of developing AMD, particularly at the early stage. | The present meta-analysis indicated that the T allelic in rs1883025 variant might be significantly associated with the risk of developing AMD, particularly at the early stage. | 1 |
This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | This meta-analysis suggests that PLEKHA7 rs11024102 is not associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | -1 |
This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | There is no evidence that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | 0 |
This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | This meta-analysis suggests that PLEKHA7 rs11024102 may be associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | 1 |
This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 does not have a genetic association with the development of PACG both in Caucasian and Asian populations. | -1 |
This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 has a genetic association with the development of PACG both in Caucasian and Asian populations. | This meta-analysis suggests that PLEKHA7 rs11024102 is associated with PACG in Asian population and COL11A1 rs3753841 may have a genetic association with the development of PACG both in Caucasian and Asian populations. | 1 |
Subthreshold micropulse diode laser treatment resulted in better visual acuity compared with conventional laser, although the differences before 12 months are likely to be too small to be of clinical relevance and may be dependent on baseline best-corrected visual acuity. | Subthreshold micropulse diode laser treatment did not result in better visual acuity compared with conventional laser, although the differences before 12 months are likely to be too small to be of clinical relevance and may be dependent on baseline best-corrected visual acuity. | -1 |
Subthreshold micropulse diode laser treatment resulted in better visual acuity compared with conventional laser, although the differences before 12 months are likely to be too small to be of clinical relevance and may be dependent on baseline best-corrected visual acuity. | Subthreshold micropulse diode laser treatment resulted in lower visual acuity compared with conventional laser, although the differences before 12 months are likely to be too small to be of clinical relevance and may be dependent on baseline best-corrected visual acuity. | -1 |
These meta-analyses demonstrate that intravitreal triamcinolone results in a temporary improvement of visual acuity in patients with laser-refractory DME, with a peak benefit of approximately 3 lines of visual acuity 1 month postinjection. | There is no evidence that intravitreal triamcinolone results in a temporary improvement of visual acuity in patients with laser-refractory DME, with a peak benefit of approximately 3 lines of visual acuity 1 month postinjection. | 0 |
These meta-analyses demonstrate that intravitreal triamcinolone results in a temporary improvement of visual acuity in patients with laser-refractory DME, with a peak benefit of approximately 3 lines of visual acuity 1 month postinjection. | These meta-analyses demonstrate that intravitreal triamcinolone may result in a temporary improvement of visual acuity in patients with laser-refractory DME, with a peak benefit of approximately 3 lines of visual acuity 1 month postinjection. | 1 |
Peripheral changes were found to be highly prevalent in eyes with AMD, supporting the claim that the disease is panretinal and not macula only. | Peripheral changes were not found to be highly prevalent in eyes with AMD, supporting the claim that the disease is panretinal and not macula only. | -1 |
Peripheral changes were found to be highly prevalent in eyes with AMD, supporting the claim that the disease is panretinal and not macula only. | Peripheral changes were found to be prevalent in eyes with AMD, supporting the claim that the disease is panretinal and not macula only. | 1 |
Findings from this research provide support that persons with AMD had a higher subsequent risk of mortality than persons without AMD. | Findings from this research provide support that persons with AMD did not have a higher subsequent risk of mortality than persons without AMD. | -1 |
Findings from this research provide support that persons with AMD had a higher subsequent risk of mortality than persons without AMD. | Findings from this research provide support that persons with AMD had a lower subsequent risk of mortality than persons without AMD. | -1 |
Findings from this research provide support that persons with AMD had a higher subsequent risk of mortality than persons without AMD. | There is no evidence that persons with AMD had a higher subsequent risk of mortality than persons without AMD. | 0 |
Findings from this research provide support that persons with AMD had a higher subsequent risk of mortality than persons without AMD. | Findings from this research provide support that persons with AMD might have a higher subsequent risk of mortality than persons without AMD. | 1 |
Our analysis shows that RBZ and RBZ combined with focal/grid laser is more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | Our analysis shows that RBZ and RBZ combined with focal/grid laser is not more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | -1 |
Our analysis shows that RBZ and RBZ combined with focal/grid laser is more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | Our analysis shows that RBZ and RBZ combined with focal/grid laser is less advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | -1 |
Our analysis shows that RBZ and RBZ combined with focal/grid laser is more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | There is no evidence that RBZ and RBZ combined with focal/grid laser is more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | 0 |
Our analysis shows that RBZ and RBZ combined with focal/grid laser is more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | Our analysis shows that RBZ and RBZ combined with focal/grid laser may be more advantageous than non-drug treatment or focal/grid laser in reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period and can be well tolerated based on the safety assessment. | 1 |
Intravitreal RBZ may be equivalent to RBZ combined with focal/grid laser. | Intravitreal RBZ may not be equivalent to RBZ combined with focal/grid laser. | -1 |
Intravitreal RBZ may be equivalent to RBZ combined with focal/grid laser. | Intravitreal RBZ may be superior to RBZ combined with focal/grid laser. | -1 |
Intravitreal RBZ may be equivalent to RBZ combined with focal/grid laser. | There is no evidence that intravitreal RBZ is equivalent to RBZ combined with focal/grid laser. | 0 |
Intravitreal RBZ may be equivalent to RBZ combined with focal/grid laser. | Intravitreal RBZ is equivalent to RBZ combined with focal/grid laser. | 1 |
Vitrectomy helps lower the PCO risk and reoperation risk after congenital cataract surgery, and also, vitrectomy helps patients gain a better BCVA and achieve a better low-contrast sensitivity, with no trade-off on IOP control, IOL deposit, synechias, uveitis and secondary glaucoma. | Vitrectomy may help lower the PCO risk and reoperation risk after congenital cataract surgery, and also, vitrectomy may help patients gain a better BCVA and achieve a better low-contrast sensitivity, with no trade-off on IOP control, IOL deposit, synechias, uveitis and secondary glaucoma. | 1 |
In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. | In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated less improvement in VA at 3 months, but not at 6 months. | -1 |
Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | Intravitreal triamcinolone acetonide injection is not effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | -1 |
Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | Intravitreal triamcinolone acetonide injection is effective in decreasing VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | -1 |
Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | Intravitreal triamcinolone acetonide injection may be effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. | 1 |
Travoprost and bimatoprost may have greater efficacy in lowering IOP for patients with OHT or glaucoma. | Travoprost and bimatoprost may not have greater efficacy in lowering IOP for patients with OHT or glaucoma. | -1 |
Travoprost and bimatoprost may have greater efficacy in lowering IOP for patients with OHT or glaucoma. | Travoprost and bimatoprost may have lesser efficacy in lowering IOP for patients with OHT or glaucoma. | -1 |
Travoprost and bimatoprost may have greater efficacy in lowering IOP for patients with OHT or glaucoma. | There is no evidence that travoprost and bimatoprost have greater efficacy in lowering IOP for patients with OHT or glaucoma. | 0 |
Travoprost and bimatoprost may have greater efficacy in lowering IOP for patients with OHT or glaucoma. | Travoprost and bimatoprost have greater efficacy in lowering IOP for patients with OHT or glaucoma. | 1 |
Our analysis provides evidence that the I62V polymorphism is associated with an increased risk of PCV. The variant of I62V could be a promising genetic biomarker of PCV in Asian populations. | Our analysis provides evidence that the I62V polymorphism may be associated with an increased risk of PCV. The variant of I62V could be a promising genetic biomarker of PCV in Asian populations. | 1 |
Our meta-analysis indicates that there is some weak evidence that increased tHcy might be associated with wet AMD; however, this result should be interpreted cautiously, because of a marked between-study heterogeneity and the possible effect of publication bias. | Our meta-analysis indicates that there is some weak evidence that increased tHcy might not be associated with wet AMD; however, this result should be interpreted cautiously, because of a marked between-study heterogeneity and the possible effect of publication bias. | -1 |
The scientific level of evidence of these articles was not high and results were inconsistent, nevertheless a promoting influence of cataract surgery on the progression of early age-related macular degeneration can be assumed. | The scientific level of evidence of these articles was not high and results were inconsistent, nevertheless a impeding influence of cataract surgery on the progression of early age-related macular degeneration can be assumed. | -1 |
This meta-analysis suggests that rs4236601[A] is associated with increased risk for POAG in Caucasian and Asian populations | This meta-analysis suggests that rs4236601[A] is not associated with increased risk for POAG in Caucasian and Asian populations | -1 |
This meta-analysis suggests that rs4236601[A] is associated with increased risk for POAG in Caucasian and Asian populations | This meta-analysis suggests that rs4236601[A] is associated with decreased risk for POAG in Caucasian and Asian populations | -1 |
This meta-analysis suggests that rs4236601[A] is associated with increased risk for POAG in Caucasian and Asian populations | There is no evidence that rs4236601[A] is associated with increased risk for POAG in Caucasian and Asian populations | 0 |
This meta-analysis suggests that rs4236601[A] is associated with increased risk for POAG in Caucasian and Asian populations | This meta-analysis suggests that rs4236601[A] may be associated with increased risk for POAG in Caucasian and Asian populations | 1 |
Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG. | Latanoprost, bimatoprost, and timolol are not the most effective IOP-lowering agents in patients with NTG. | -1 |
Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG. | Latanoprost, bimatoprost, and timolol are the most ineffective IOP-lowering agents in patients with NTG. | -1 |
Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG. | There is no evidence that latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG. | 0 |
Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG. | Latanoprost, bimatoprost, and timolol may be the most effective IOP-lowering agents in patients with NTG. | 1 |